Medivation Inc (MDVN) 65.91 $MDVN
Medivation Announces Participation at Upcoming Investor Conferences
Marketwire - Mon May 12, 1:53PM CDT
Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conferences:
Strength Seen in Medivation (MDVN): Stock Up 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:25AM CDT
Medivation (MDVN) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
Top Gainers Technical Data -- Research on BioScrip, Medivation, Array BioPharma, and Doral Financial
PR Newswire - Mon May 12, 7:17AM CDT
The US markets saw a positive sentiment on Friday, May 09, 2014, with the NASDAQ Composite closing at 4,071.87, up 0.50%, the Dow Jones Industrial Average ending the session at 16,583.34, up 0.20% and the S&P 500 edging 0.15% higher to finish the trading session at 1,878.48. The session saw a positive impact from Consumer Discretionary, Health Care and Consumer Staples sectors along with a drag from Financials, Energy and Utilities sectors. A number of stocks saw large movements, including BioScrip Inc. (NASDAQ: BIOS), Medivation Inc. (NASDAQ: MDVN), Array BioPharma Inc. (NASDAQ: ARRY) and Doral Financial Corporation (NYSE: DRL). Free technical research on BIOS, MDVN, ARRY and DRL can be downloaded upon signing up at:
Is Dendreon Back on Solid Ground?
Todd Campbell, The Motley Fool - Motley Fool - Sun May 11, 1:30PM CDT
Prostate cancer is one of the most common forms of cancer. It affects millions of men worldwide and costs billions to treat. This year alone, some 192,000 new cases will be diagnosed, and between 2010 and 2020, Americans' spending on prostate cancer...
What You Need to Know About Medivation Inc.'s Results
Todd Campbell, The Motley Fool - Motley Fool - Sun May 11, 8:00AM CDT
Medivation shares tumbled in February when it warned sequential sales growth would slow this year, a promise the company kept when it reported its first-quarter earnings last week. Medivation's only commercialized drug is the prostate cancer...
Look for Shares of Medivation to Potentially Pullback after Yesterday's 8.52% Rise
Comtex SmarTrend(R) - Fri May 09, 3:59PM CDT
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $62.52 to a high of $66.50. Yesterday, the shares gained 8.5%, which took the trading range above the 3-day high of $64.20 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Medivation Inc. Shares Roared Higher
Sean Williams, The Motley Fool - Motley Fool - Fri May 09, 11:39AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Medivation , a biopharmaceutical company...
Medivation Q1 Loss Wider Than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 9:10AM CDT
Although Medivation (MDVN) missed expectations, Xtandi's performance was strong and guidance was raised.
Medivation (MDVN) Is Today's Dead Cat Bounce Stock
at The Street - Fri May 09, 8:47AM CDT
Trade-Ideas LLC identified Medivation (MDVN) as a "dead cat bounce" (down big yesterday but up big today) candidate
Medivation's Q1 Loss Shrinks by 50% as Xtandi Revenue Soars
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 5:27PM CDT
Cancer-drug developer Medivation continued to demonstrate the steady progress of its late-stage prostate cancer treatment Xtandi with its first-quarter earnings release after the closing bell. For the quarter, Medivation's collaborative...
Medivation Reports First Quarter Financial Results and Provides Corporate Update
Marketwire - Thu May 08, 3:10PM CDT
Medivation, Inc. (NASDAQ: MDVN) today provided a corporate update and reported its financial results for the first quarter ended March 31, 2014. U.S. net sales of XTANDI(R) (enzalutamide) capsules for the quarter, as reported by Astellas, were $124.5 million. Ex-U.S. net sales of XTANDI for the quarter, as reported by Astellas, were $47.8 million.
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic
Medivation Down 13.5% Since SmarTrend Downtrend Call (MDVN)
Comtex SmarTrend(R) - Wed May 07, 5:00PM CDT
SmarTrend identified a Downtrend for Medivation (NASDAQ:MDVN) on February 28th, 2014 at $73.43. In approximately 2 months, Medivation has returned 13.53% as of today's recent price of $63.49.
Will Regeneron (REGN) Disappoint in Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 4:20PM CDT
Regeneron (REGN) is set to report its first quarter 2014 results on Feb 8 before the opening bell.
A View on Ariad Pharma's Bloated Valuation
at The Street - Wed May 07, 11:49AM CDT
Even at $86 million in 2014 Iclusig sales, Ariad trades at a lofty and unjustified 13 times enterprise value. For comparison's sake, Medivation's EV/sales multiple is 9 -- and that's only counting U.S. sales of its growing prostate cancer drug...
Memorial Sloan-Kettering's Dr. Howard Scher Reaffirms Commitment to Lead Phase I Trials for AV Therapeutics' Prostate Cancer Drug
GlobeNewswire - Wed May 07, 9:14AM CDT
AV Therapeutics, Inc. ("AV Therapeutics" or the "Company"
(OTCQB:AVTH), a developer of cancer therapeutics and vaccines, announced Howard Scher, MD, Chief, Genitourinary Oncology Service and D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center, reaffirmed his commitment to lead AV Therapeutics' Phase I clinical trial for its prostate cancer immunotherapy drug, Capridine-β.
Biotech Stock Roundup: Endocyte Tumbles & Merrimack Soars on Pipeline News - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed May 07, 8:34AM CDT
Several companies reported earnings and provided regulatory and pipeline updates last week.
Astellas and Medivation Receive Priority Review From FDA for XTANDI(R) (Enzalutamide) Capsules in Chemotherapy-Naive Advanced Prostate Cancer
Marketwire - Wed May 07, 5:07AM CDT
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) to extend the indication for XTANDI(R) (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. This sNDA application was granted Priority Review designation with a stated FDA Prescription Drug User Fee Act (PDUFA) review date of September 18, 2014. XTANDI is currently approved for the treatment of patients with mCRPC who have previously received docetaxel chemotherapy.
Tuesday’s Top Health Care Stories: Bayer, Merck, Medivation, and AstraZeneca
Leo Sun, The Motley Fool - Motley Fool - Tue May 06, 8:18AM CDT
Let's take a look at four stocks -- Bayer , Merck , Medivation , and AstraZeneca -- which could all make waves across the health care sector this Tuesday morning. Bayer acquires Merck's consumer care business for $14.2 billion ...
Why Earnings Season Could Be Great for Medivation (MDVN) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 7:30AM CDT
Medivation (MDVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. The company looks set to produce a positive earnings surprise and outperform the market.
Medivation Announces Participation at Upcoming Investor Conferences
Marketwire - Mon May 12, 1:53PM CDT
Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conferences:
Strength Seen in Medivation (MDVN): Stock Up 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:25AM CDT
Medivation (MDVN) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
Top Gainers Technical Data -- Research on BioScrip, Medivation, Array BioPharma, and Doral Financial
PR Newswire - Mon May 12, 7:17AM CDT
The US markets saw a positive sentiment on Friday, May 09, 2014, with the NASDAQ Composite closing at 4,071.87, up 0.50%, the Dow Jones Industrial Average ending the session at 16,583.34, up 0.20% and the S&P 500 edging 0.15% higher to finish the trading session at 1,878.48. The session saw a positive impact from Consumer Discretionary, Health Care and Consumer Staples sectors along with a drag from Financials, Energy and Utilities sectors. A number of stocks saw large movements, including BioScrip Inc. (NASDAQ: BIOS), Medivation Inc. (NASDAQ: MDVN), Array BioPharma Inc. (NASDAQ: ARRY) and Doral Financial Corporation (NYSE: DRL). Free technical research on BIOS, MDVN, ARRY and DRL can be downloaded upon signing up at:
Is Dendreon Back on Solid Ground?
Todd Campbell, The Motley Fool - Motley Fool - Sun May 11, 1:30PM CDT
Prostate cancer is one of the most common forms of cancer. It affects millions of men worldwide and costs billions to treat. This year alone, some 192,000 new cases will be diagnosed, and between 2010 and 2020, Americans' spending on prostate cancer...
What You Need to Know About Medivation Inc.'s Results
Todd Campbell, The Motley Fool - Motley Fool - Sun May 11, 8:00AM CDT
Medivation shares tumbled in February when it warned sequential sales growth would slow this year, a promise the company kept when it reported its first-quarter earnings last week. Medivation's only commercialized drug is the prostate cancer...
Look for Shares of Medivation to Potentially Pullback after Yesterday's 8.52% Rise
Comtex SmarTrend(R) - Fri May 09, 3:59PM CDT
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $62.52 to a high of $66.50. Yesterday, the shares gained 8.5%, which took the trading range above the 3-day high of $64.20 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Medivation Inc. Shares Roared Higher
Sean Williams, The Motley Fool - Motley Fool - Fri May 09, 11:39AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Medivation , a biopharmaceutical company...
Medivation Q1 Loss Wider Than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 9:10AM CDT
Although Medivation (MDVN) missed expectations, Xtandi's performance was strong and guidance was raised.
Medivation (MDVN) Is Today's Dead Cat Bounce Stock
at The Street - Fri May 09, 8:47AM CDT
Trade-Ideas LLC identified Medivation (MDVN) as a "dead cat bounce" (down big yesterday but up big today) candidate
Medivation's Q1 Loss Shrinks by 50% as Xtandi Revenue Soars
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 5:27PM CDT
Cancer-drug developer Medivation continued to demonstrate the steady progress of its late-stage prostate cancer treatment Xtandi with its first-quarter earnings release after the closing bell. For the quarter, Medivation's collaborative...
Medivation Reports First Quarter Financial Results and Provides Corporate Update
Marketwire - Thu May 08, 3:10PM CDT
Medivation, Inc. (NASDAQ: MDVN) today provided a corporate update and reported its financial results for the first quarter ended March 31, 2014. U.S. net sales of XTANDI(R) (enzalutamide) capsules for the quarter, as reported by Astellas, were $124.5 million. Ex-U.S. net sales of XTANDI for the quarter, as reported by Astellas, were $47.8 million.
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic
Medivation Down 13.5% Since SmarTrend Downtrend Call (MDVN)
Comtex SmarTrend(R) - Wed May 07, 5:00PM CDT
SmarTrend identified a Downtrend for Medivation (NASDAQ:MDVN) on February 28th, 2014 at $73.43. In approximately 2 months, Medivation has returned 13.53% as of today's recent price of $63.49.
Will Regeneron (REGN) Disappoint in Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 4:20PM CDT
Regeneron (REGN) is set to report its first quarter 2014 results on Feb 8 before the opening bell.
A View on Ariad Pharma's Bloated Valuation
at The Street - Wed May 07, 11:49AM CDT
Even at $86 million in 2014 Iclusig sales, Ariad trades at a lofty and unjustified 13 times enterprise value. For comparison's sake, Medivation's EV/sales multiple is 9 -- and that's only counting U.S. sales of its growing prostate cancer drug...
Memorial Sloan-Kettering's Dr. Howard Scher Reaffirms Commitment to Lead Phase I Trials for AV Therapeutics' Prostate Cancer Drug
GlobeNewswire - Wed May 07, 9:14AM CDT
AV Therapeutics, Inc. ("AV Therapeutics" or the "Company"
(OTCQB:AVTH), a developer of cancer therapeutics and vaccines, announced Howard Scher, MD, Chief, Genitourinary Oncology Service and D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center, reaffirmed his commitment to lead AV Therapeutics' Phase I clinical trial for its prostate cancer immunotherapy drug, Capridine-β. Biotech Stock Roundup: Endocyte Tumbles & Merrimack Soars on Pipeline News - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed May 07, 8:34AM CDT
Several companies reported earnings and provided regulatory and pipeline updates last week.
Astellas and Medivation Receive Priority Review From FDA for XTANDI(R) (Enzalutamide) Capsules in Chemotherapy-Naive Advanced Prostate Cancer
Marketwire - Wed May 07, 5:07AM CDT
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) to extend the indication for XTANDI(R) (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. This sNDA application was granted Priority Review designation with a stated FDA Prescription Drug User Fee Act (PDUFA) review date of September 18, 2014. XTANDI is currently approved for the treatment of patients with mCRPC who have previously received docetaxel chemotherapy.
Tuesday’s Top Health Care Stories: Bayer, Merck, Medivation, and AstraZeneca
Leo Sun, The Motley Fool - Motley Fool - Tue May 06, 8:18AM CDT
Let's take a look at four stocks -- Bayer , Merck , Medivation , and AstraZeneca -- which could all make waves across the health care sector this Tuesday morning. Bayer acquires Merck's consumer care business for $14.2 billion ...
Why Earnings Season Could Be Great for Medivation (MDVN) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 7:30AM CDT
Medivation (MDVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. The company looks set to produce a positive earnings surprise and outperform the market.
